Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

PHASE3CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

September 10, 2025

Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
BIOLOGICAL

Pembrolizumab

Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.

DRUG

Enzalutamide

Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.

DRUG

Androgen Deprivation Therapy (ADT)

Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.

OTHER

Placebo

Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.

Trial Locations (24)

100034

Peking University First Hospital ( Site 0800), Beijing

100142

Beijing Cancer Hospital ( Site 0802), Beijing

150081

Harbin Medical University Cancer Hospital ( Site 0822), Harbin

200127

Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0807 ), Shanghai

210008

Nanjing Drum Tower Hospital ( Site 0811), Nanjing

300000

Tianjin Medical University Cancer Institute & Hospital ( Site 0804 ), Tianjin

310009

2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0808), Hangzhou

The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 0830), Hangzhou

310014

Zhejiang Provincial People's Hospital ( Site 0809), Hangzhou

315010

Ningbo First Hospital-Urology (0835), Ningbo

325000

The First Affiliated Hospital of Wenzhou Medical University ( Site 0834), Wenzhou

330006

The First Affiliated Hospital of Nanchang University ( Site 0821), Nanchang

361000

The First Affiliated Hospital of Xiamen University (Site 0816), Xiamen

400030

Chongqing Cancer Hospital ( Site 0815), Chongqing

410013

Hunan Cancer Hospital ( Site 0817), Changsha

430000

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0829), Wuhan

430079

Hubei Cancer Hospital ( Site 0833), Wuhan

450008

Henan Cancer Hospital ( Site 0818), Zhengzhou

510060

Sun Yat-Sen University Cancer Center ( Site 0825), Guangzhou

510120

The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 0638), Guangzhou

510220

Sun Yat Sen Memorial Hospital (Site # 0819), Guangzhou

510515

Southern Medical University Nanfang Hospital ( Site 0838), Guangzhou

710004

The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831), Xi'an

710061

The first affiliated Hospital of Xi an Jiaotong University ( Site # 0812), Xi’an

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY